News NHS use of Incyte's anal cancer drug Zynyz backed by NICE Hundreds of patients in England and Wales with anal cancer could soon be eligible for treatment with Incyte's cancer immunotherapy Zynyz.
News UK pilots shorter NICE appraisal for new medicines NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months.
News NICE backs Keytruda/Padcev combo for bladder cancer Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
News EVERSANA builds its AI Agency with Estima acquisition EVERSANA has acquired UK AI-powered health economics and outcomes research (HEOR) firm Estima to help its customers "modernise commercialisation."
News Five AI tools to spot prostate cancer backed for NHS use NICE has backed temporary NHS use of five AI tools that can help detect prostate cancer on MRI scans, while more evidence on their value is gathered.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.